Wednesday, October 25, 2017
5:30 to 8:00 pm
Greehey Children’s Cancer Research Institute (GCCRI)
8403 Floyd Curl Drive, San Antonio, TX 78229
Karin Hehenberger, MD, Ph.D., Founder & CEO of Lyfebulb
“How Patients are Driving Innovation in the Future Healthcare Environment ”
Dr. Karin Hehenberger is an experienced life sciences executive who has dedicated her career to applying medical science to impact the lives of people living with chronic disease. Dr. Hehenberger founded and launched Lyfebulb in January of 2014, after close to 20 years of experience in the healthcare industry. She earned both M.D. and Ph.D. degrees from the Karolinska Institute in Stockholm, Sweden and conducted her post-doctoral work as a JDRF fellow at the Joslin Diabetes Center at Harvard Medical School. Lyfebulb is focused on bringing innovative and impactful biopharmaceutical, medical device, and consumer products to market. The overall mission is to improve the quality of life for people living with chronic disease, with a special focus on investing in diabetes innovation by leveraging the lived experience of patient entrepreneurs. Dr. Hehenberger has held leadership positions in the biopharmaceutical industry, including at Johnson & Johnson, Eyetech Pharmaceuticals and Coronado biosciences, as well as on the investment side of healthcare at both private and public multi-billion dollar funds. Dr. Hehenberger is considered an expert in the field of metabolic disease and is an invited speaker at numerous conferences and at corporate strategy sessions on this topic, as well as the subject of patient impact, innovation and alternative financing methods for early stage research. She recently gave a TEDX talk in Lugano, Switzerland on the importance of patient involvement in reversing the global diabetes pandemic. Read the latest on Dr. Hehenberger's work at Lyfebulb in Forbes here.
Sponsorship provided by